by
Thomas Dworetzky, Contributing Reporter | May 24, 2017
In April,
a study on COPD treatment co-sponsored by Philips, found that the combination of noninvasive ventilation and home oxygen therapy can prolong time to readmission or death for patients who have had a life-threatening respiratory event.
"Noninvasive ventilation (NIV) assists patients with their breathing by providing a prescribed pressure or volume of air during inhalation," Dr. Teofilo Lee-Chiong, chief medical liaison for Philips, and professor of medicine at National Jewish Hospital and the University of Colorado, told HCB News. "Newer technologies, such as the AVAPS-AE mode used in the study with Philips Trilogy, are more responsive to the patient's ever-changing breathing needs."
Ad Statistics
Times Displayed: 3029
Times Visited: 33 Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.
The study found a $402,981 savings over 30 days and a $449,101 savings over 90 days for 250 patients. Further, in a related payor-based case analysis of 100,000 patients, the study calculated a three-year savings of $326 million for patients treated with the advanced care NIV, and $1.04 billion in savings compared to no NIV treatment.
Back to HCB News
